Eton Pharmaceuticals Reports Second Quarter Financial Results
Eton Pharmaceuticals, Inc. (ETON)
Last eton pharmaceuticals, inc. earnings: 3/5 04:02 pm
Check Earnings Report
Company Research
Source: GlobeNewswire
DEER PARK, Ill., Aug. 16, 2021 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc (Nasdaq: ETON), an innovative pharmaceutical company focused on developing and commercializing treatments for rare diseases, today reported financial results for the second quarter ended June 30, 2021. “During the second quarter we received FDA-approval for Rezipres®, which is now the fourth FDA-approved product in our portfolio,” said Sean Brynjelsen CEO of Eton Pharmaceuticals. “We look forward to launching Rezipres® in the coming months. We also expanded our pediatric endocrinology portfolio with the acquisition of U.S. and Canadian rights to the ZENEO® Hydrocortisone autoinjector. ZENEO Hydrocortisone is a terrific strategic fit with ALKINDI SPRINKLE, and we look forward to working with Crossject to bring it to market as quickly as possible.” Second Quarter Business Highlights Received U.S. Food and Drug Administration (FDA) approval of Rezipres®, a ready-to-use formulation of ephedrine injection. Et
Show less
Read more
Impact Snapshot
Event Time:
ETON
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
ETON alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
ETON alerts
High impacting Eton Pharmaceuticals, Inc. news events
Weekly update
A roundup of the hottest topics
ETON
News
- Relief Therapeutics Enters into Exclusive U.S. License and Supply Agreement with Eton Pharmaceuticals for PKU GOLIKE [Yahoo! Finance]Yahoo! Finance
- Eton Pharmaceuticals Announces Acquisition of PKU GOLIKE® for Phenylketonuria [Yahoo! Finance]Yahoo! Finance
- Eton Pharmaceuticals Announces Acquisition of PKU GOLIKE® for PhenylketonuriaGlobeNewswire
- Harrow Health Non-GAAP EPS of -$0.20 misses by $0.15, revenue of $36.36M misses by $1.5M [Seeking Alpha]Seeking Alpha
- Eton Pharmaceuticals, Inc. (NASDAQ:ETON) Q4 2023 Earnings Call Transcript [Yahoo! Finance]Yahoo! Finance
ETON
Earnings
- 3/14/24 - Miss
ETON
Sec Filings
- 3/26/24 - Form S-8
- 3/22/24 - Form 10-K/A
- 3/22/24 - Form 8-K
- ETON's page on the SEC website